Related Experiment Video
Updated: Sep 16, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.3K
Multicenter Retrospective Study of Stereotactic Radiosurgery for Gynecological Cancer Brain Metastases
Mathilde Billau1, Andréanne Hamel1, Jean-Nicolas Tourigny1
1Service de Neurochirurgie, Université de Sherbrooke, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke , Quebec , Canada.
Neurosurgery
|July 7, 2025
Summary
Stereotactic radiosurgery (SRS) effectively manages brain metastases (BM) from gynecological cancers, offering good local control and survival rates. This treatment shows a low risk of symptomatic adverse radiation effects, making it a viable option for patients.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Gynecologic Oncology
Background:
- Brain metastases (BM) from gynecological cancers are uncommon but challenging to manage.
- Limited evidence exists regarding the efficacy of stereotactic radiosurgery (SRS) for these specific BM.
Purpose of the Study:
- To investigate the role and outcomes of SRS in patients with BM originating from primary gynecological cancers.
- To evaluate survival, local control, and adverse radiation effects (ARE) associated with SRS for gynecological cancer BM.
Main Methods:
- Retrospective analysis of 276 patients with histologically confirmed epithelial ovarian, cervical, or endometrial cancer and BM treated with SRS between 2000 and 2020.
- Data collected included patient demographics, primary cancer type, SRS details (dose, fractionation), and follow-up for survival, local control, and ARE.
Main Results:
- Actuarial overall survival rates were 77% at 6 months, 65% at 12 months, and 44% at 24 months.
- High actuarial local control rates were observed: 94% at 6 months, 89% at 12 months, and 78% at 24 months.
- Symptomatic adverse radiation effects (ARE) were low, occurring in only 3% of patients, although 13% experienced any ARE.
Conclusions:
- Stereotactic radiosurgery (SRS) is an effective treatment modality for brain metastases from gynecological cancers.
- SRS provides durable local control and acceptable survival rates with a low risk of significant adverse radiation effects.
